Trial Profile
Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUTHREE
- 08 Mar 2018 New trial record